drugset / Trial / NCT00064337
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Phase 2
Completed
104 enrolled
SWOG Cancer Research Network
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving melphalan together with autologous stem cell transplantation works in treating patients with multiple myeloma or primary systemic amyloidosis.
Timeline
- Start
- 2004-01
- Primary completion
- 2012-05
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 100 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 2500 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Thalidomide | Other / unclassified | 100 mg | Oral |
| Background | filgrastim | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | 16 ug/kg | Subcutaneous |